[1] Gill K S,Muntner P,Lafayette R A,et al.Red blood cell transfusion use in patients with chronic kidney disease[J]. Nephrol Dial Transplant,2013,28(6):1504-1515. [2] Collins A J,Monda K L,Molony J T,et al.Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion[J]. Am J Kidney Dis,2014, 63(6):997-1006. [3] Cappell K A,Shreay S,Cao Z,et al.Red blood cell (RBC) transfusion rates among US chronic dialysis patients during changes to Medicare end-stage renal disease (ESRD) reimbursement systems and erythropoiesis stimulating agent (ESA) labels[J]. BMC Nephrol,2014, 15:116. [4] Pavlou E G,Georgatzakou H T,Fortis S P,et al.Coagulation abnormalities in renal pathology of chronic kidney disease: the interplay between blood cells and soluble factors[J]. Biomolecules,2021,11(9):1309. [5] Hendrickson J E,Hillyer C D.Noninfectious serious hazards of transfusion[J]. Anesth Analg,2009,108(3): 759-769. [6] De La Vega-Méndez F M,Estrada M I,Zuno-Reyes E E, et al. Blood transfusion reactions and risk of acute kidney injury and major adverse kidney events[J]. J Nephrol, 2024,37(4):951-960. [7] 马志军,程连赛,武永胜,等. 临床输血不良反应发生率及其下降原因[J]. 临床血液学杂志,2015,28(6):499-501. [8] 马砚敏,张涛. 肾功能不全患者血液透析后输血反应的观察与分析[J]. 中国实用医药,2015,10(8):125-126. [9] Bulle E B,Klanderman R B,Pendergrast J,et al.The recipe for TACO: A narrative review on the pathophysiology and potential mitigation strategies of transfusion-associated circulatory overload[J]. Blood Rev,2022,52:100891. [10] Kapur R.Key features of the underlying pathophysiology of Transfusion-related acute lung injury[J]. Expert Rev Hematol,2025,18(1):57-64. [11] Chan B,Varghese A,Badve S V,et al.Systematic review of the effects of iron on cardiovascular,kidney,and safety outcomes in patients with CKD[J]. Kidney Int Rep,2025, 10(4):1037-1049. [12] Eschbach J W,Adamson J W.Iron overload in renal failure patients: Changes since the introduction of erythropoietin therapy[J]. Kidney Int,1999,55:S35-S43. [13] Rostoker G,Vaziri N D.Risk of iron overload with chronic indiscriminate use of intravenous iron products in ESRD and IBD populations[J]. Heliyon,2019,5(7): e02045. [14] Rostoker G.When should iron supplementation in dialysis patients be avoided,minimized or withdrawn?[J]. Semin Dial,2019,32(1):22-29. [15] Piccin A,Cronin M,Brady R,et al.Transfusion-associated circulatory overload in Ireland: a review of cases reported to the National Haemovigilance Office 2000 to 2010[J]. Transfusion,2015,55(6):1223-1230. [16] Li G X,Rachmale S,Kojicic M,et al.Incidence and transfusion risk factors for transfusion-associated circulatory overload among medical intensive care unit patients[J]. Transfusion,2011,51(2):338-343. [17] Soni L,Saeed S,Cserti-Gazdewich C,et al.Mortality-associated risk factors for transfusion-associated circulatory overload[J]. Vox Sang,2024,119(9):996-1000. [18] Marshall A L,Levine M,Howell M L,et al.Dose‐associated pulmonary complication rates after fresh frozen plasma administration for warfarin reversal[J]. J Thromb Haemost,2016,14(2):324-330. [19] White S K,Walker B S,Schmidt R L,et al.The incidence of transfusion-related acute lung injury using active surveillance: A systematic review and meta-analysis[J]. Transfusion,2024,64(2):289-300. [20] Toy P,Looney M R,Popovsky M,et al.Transfusion-related acute lung injury: 36 years of progress (1985—2021)[J]. Ann Am Thorac Soc,2022,19(5):705-712. [21] Triulzi D J.Transfusion-related acute lung injury: current concepts for the clinician[J]. Anesth Analg,2009, 108(3):770-776. [22] Benson A B,Moss M,Silliman C C.Transfusion-related acute lung injury (TRALI): a clinical review with emphasis on the critically ill[J]. Br J Haematol,2009, 147(4):431-443. [23] Israelyan N,Vege S,Friedman D F,et al.RH genotypes and red cell alloimmunization rates in chronically transfused patients with sickle cell disease: A multisite study in the USA[J]. Transfusion,2024,64(3):526-535. [24] Habibi B,Lecolier B.Inconvenience of planned prophylaxis of transfusion-induced alloimmunization to red cells in chronic renal insufficiency[J]. Rev Fr Transfus Immunohematol,1983,26(3):267-277. [25] Nebie K,Sawadogo S,Sawadogo S,et al.Red blood cell alloimmunisation in multi-transfused patients from an haemodialysis service in Burkina Faso[J]. Afr J Lab Med,2022,11(1):1625. [26] Hung S Y,Hung I H,Yang Y T,et al.Frequent transfusion and specific HLA-DRB1 alleles correlate independently with Miltenberger blood group alloimmunization in dialysis patients[J]. HLA,2020,96(2):186-191. [27] Fonseca H E,Chiba A K,Fabron Junior A,et al.Anti-N-like and anti-Form red cell antibodies in chronic hemodialysis patients[J]. Ren Fail,2004,26(5):553-556. [28] 侯瑞琴,杨洪燕,崔银平,等. 患者不规则抗体鉴定结果分析及其临床意义[J]. 中国实验血液学杂志,2020,28(3): 961-966. [29] 李小飞,马春娅,蔡晓红,等. 红细胞血型抗原拓展匹配适用范围中国专家共识[J]. 临床输血与检验,2024,26(3): 289-298. [30] Tanhehco Y C,Berns J S.Red blood cell transfusion risks in patients with end-stage renal disease[J]. Semin Dial,2012,25(5):539-544. [31] Gaweda A E,Ginzburg Y Z,Chait Y,et al.Iron dosing in kidney disease: inconsistency of evidence and clinical practice[J]. Nephrol Dial Transplant,2015,30(2):187-196. [32] Fong I W.Blood transfusion-associated infections in the twenty-first century: new challenges[M]//Current Trends and Concerns in Infectious Diseases. Cham:Springer International Publishing,2020:191-215. [33] Seifried E,Schmidt M.Sicherheit der blutprodukte-update 2024[J]. Transfusionsmedizin,2024,14(1):34-45. [34] Lelie N,Busch M,Kleinman S.Efficacy of different testing scenarios in reducing transfusion-transmitted hepatitis B virus (TT-HBV) infection risk[J]. Viruses, 2022,14(10):2263. [35] Liu W J,Yu C M,Chen Y Y,et al.Trends in donor infection profiles and residual risks of transfusion-transmitted human immunodeficiency virus,hepatitis C virus and hepatitis B virus after the implementation of universal mini-pool nucleic acid testing in Taiwan[J]. Vox Sang,2025,120(10):995-1003. [36] Kühn J E.Transfusion-associated infections with cytomegalovirus and other human herpesviruses[J]. Infusionsther Transfusionsmed,2000,27(3):138-143. [37] Ziemann M,Hennig H.Prevention of transfusion-transmitted cytomegalovirus infections: which is the optimal strategy?[J]. Transfus Med Hemother,2014,41(1): 40-44. [38] Moreira-Soto A,Postigo-Hidalgo I,Tabares X,et al.Transfusion-transmitted infections: risks and mitigation strategies for Oropouche virus and other emerging arboviruses in Latin America and the Caribbean[J]. Lancet Reg Health Am,2025,46:101089. [39] Kopolovic I,Ostro J,Tsubota H,et al.A systematic review of transfusion-associated graft-versus-host disease[J]. Blood,2015,126(3):406-414. [40] Manduzio P.Transfusion-associated graft-versus-host disease: A concise review[J]. Hematol Rep,2018,10(4): 7724. [41] Baaten C C F M J,Sternkopf M,Henning T,et al. Platelet function in CKD: a systematic review and meta-analysis[J]. JASN,2021,32(7):1583-1598. [42] Lutz J, Jurk K.Platelets in advanced chronic kidney disease: two sides of the coin[J]. Semin Thromb Hemost, 2020,46(3):342-356. [43] Haysom R,Aziz N,Swan D,et al.Bleeding in patients with renal impairment: a current perspective[J]. Semin Thromb Hemost,2026,52(6):645-652. [44] Carminita E,Camacho V,Branfield S,et al.Platelet dysfunction in chronic kidney disease arises from bone marrow remodeling and megakaryocyte reprogramming[J]. Blood Adv,2026,10(5):1444-1456. [45] Ali S,Botnarciuc M,Daba L C,et al.Efficiency of platelet transfusion in patients with moderate-to-severe chronic kidney disease and thrombocytopenia[J]. Int J Mol Sci,2023,24(21):15895. [46] 维持性血液透析合并肾性贫血临床管理中国专家共识(2026版)工作组. 维持性血液透析合并肾性贫血临床管理中国专家共识(2026版)[J]. 中国血液净化,2026,25(5): 353-369. [47] Pothacamuri M A,Venugopal A,Chandrashekar N,et al.Erythropoiesis-stimulating agents (ESAs) in chronic kidney disease and cancer-related anemia: a narrative review of literature[J]. Cureus,2025,17(9):e93584. [48] CHUNG E Y M, PALMER S C, SAGLIMBENE V M, et al. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis[J]. Cochrane Database of Systematic Reviews, 2023(2):CD010590. [49] Singh A K,Carroll K,Perkovic V,et al.Daprodustat for the treatment of anemia in patients undergoing dialysis[J]. N Engl J Med,2021,385(25):2325-2335. [50] Toka H R,Bernardo M,Burke S K,et al. Vadadustat three times weekly in patients with anemia due to dialysis-dependent CKD[J]. Am J Kidney Dis,2025,85(4):454-464.e1. [51] TYAGI J, KAUR M, INGALE S, et al.Hypoxia-inducible factor prolyl hydroxylase inhibitors for anemia in dialysis-dependent chronic kidney disease: systematic review and meta-analysis of randomized controlled trials[J]. Indian Journal of Nephrology,2025, 35(2):198-216. [52] Stoumpos S,Crowe K,Sarafidis P,et al.Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a clinical practice document by the European Renal Best Practice board of the European Renal Association[J]. Nephrol Dial Transpl,2024,39(10): 1710-1730. [53] Kidney Disease:Improving Global Outcomes KDIGO Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease[J]. Kidney Int Suppl,2012,2(4):S279-S335. [54] del Vecchio L,Cases A,Eisenga M F,et al. KDIGO 2026 clinical practice guideline for anemia in chronic kidney disease (CKD): a commentary from the European renal best practice (ERBP)[J]. Nephrol Dial Transplant,2026, 41(8):1554-1572. [55] 中国医师协会肾脏内科医师分会肾性贫血指南工作组,陈香美,孙雪峰. 中国肾性贫血诊治临床实践指南[J]. 中华医学杂志,2021,101(20):1463-1502. [56] Franchini M,Marano G,Veropalumbo E,et al.Patient Blood Management: a revolutionary approach to transfusion medicine[J]. Blood Transfus,2019,17(3):191-195. [57] Butcher A,Richards T.Cornerstones of patient blood management in surgery[J]. Transfus Med,2018,28(2): 150-157. [58] Céspedes I C,Figueiredo M S,Hossne Junior N A,et al. Patient blood management program implementation: comprehensive recommendations and practical strategies[J]. Braz J Cardiovasc Surg,2024,39(5):e20240205. [59] Shander A,Van Aken H,Colomina M J,et al.Patient blood management in Europe[J]. Br J Anaesth,2012,109(1): 55-68. [60] Schonewille H,van de Watering L M,Brand A. Additional red blood cell alloantibodies after blood transfusions in a nonhematologic alloimmunized patient cohort: is it time to take precautionary measures?[J]. Transfusion,2006,46(4):630-635. [61] 中华人民共和国国家卫生健康委员会. WS/T 622—2018 内科输血[S]. 2018. [62] 中华人民共和国国家卫生健康委员会. WS/T 623—2018 全血和成分血使用[S]. 2018. [63] 中华人民共和国国家卫生健康委员会. WS/T 624—2018 输血反应分类[S]. 2018. |